切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2026, Vol. 20 ›› Issue (06) : 424 -432. doi: 10.3877/cma.j.issn.1674-0785.2026.06.003

临床研究

大分割放疗在肺癌肺寡进展中的有效性及安全性
毛裔龙, 刘磊, 郭磊磊, 李晨聪, 孔姝颖, 王艺茜†()   
  1. 116000 辽宁大连,大连医科大学附属第一医院放疗科
  • 收稿日期:2026-05-15 出版日期:2026-06-30
  • 通信作者: 王艺茜

Efficacy and safety of hypofractionated radiotherapy in pulmonary oligometastases from non-small cell lung cancer

Yilong Mao, Lei Liu, Leilei Guo, Chencong Li, Shuying Kong, Yiqian Wang†()   

  1. Department of Radiation Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian 116000, China
  • Received:2026-05-15 Published:2026-06-30
  • Corresponding author: Yiqian Wang
引用本文:

毛裔龙, 刘磊, 郭磊磊, 李晨聪, 孔姝颖, 王艺茜. 大分割放疗在肺癌肺寡进展中的有效性及安全性[J/OL]. 中华临床医师杂志(电子版), 2026, 20(06): 424-432.

Yilong Mao, Lei Liu, Leilei Guo, Chencong Li, Shuying Kong, Yiqian Wang. Efficacy and safety of hypofractionated radiotherapy in pulmonary oligometastases from non-small cell lung cancer[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2026, 20(06): 424-432.

目的

本研究旨在评估大分割放疗在非小细胞肺癌肺寡进展治疗中的有效性及安全性。

方法

回顾性收集2019年11月至2023年6月期间大连医科大学附属第一医院收治的141例一线治疗后仅肺转移灶局部寡进展的晚期非小细胞肺癌肺寡转移患者,男性93例,女性48例,中位年龄66岁,将入组的141例患者进行倾向性评分匹配(PSM),卡钳值设为0.2,以1∶1的比例进行,根据是否进行肺转移灶大分割放疗分为大分割放疗(HFRT)组(n=47)和标准治疗(SOC)组(n=94),全身治疗方案均按照指南推荐的标准治疗进行,所有的放疗患者均采用旋转容积弧形调强放疗(VMAT),比较2组的近期疗效、PFS、OS及安全性。Kaplan-Meier法计算生存率,Cox回归模型多因素预后分析。

结果

共匹配到82例患者,2组各41例。中位随访时间32.1个月,HFRT组在近期疗效(P=0.038)及PFS(P=0.037)和OS(P=0.038)方面均优于SOC组,其中,PFS的独立预后因素为是否联合HFRT、全身治疗方案;OS的独立预后因素为是否联合HFRT、全身治疗方案、转移灶数量,毒副反应均可控。

结论

对于一线全身治疗后发生肺寡进展的晚期非小细胞肺癌(NSCLC)肺寡转移人群,特别是驱动基因阴性、接受免疫+化疗的患者,对转移灶行大分割放疗可在保证安全的前提下取得较好的结果。

Objective

To evaluate the efficacy and safety of hypofractionated radiotherapy (HFRT) in the treatment of pulmonary oligometastases originating from non-small cell lung cancer (NSCLC).

Methods

We retrospectively enrolled 141 patients with advanced NSCLC who developed isolated pulmonary oligometastatic progression following first-line systemic therapy at the First Affiliated Hospital of Dalian Medical University between November 2019 and June 2023. The cohort comprised 93 males and 48 females, with a median age of 66 years. Propensity score matching (PSM) was performed using a caliper of 0.2 at a 1∶1 ratio, yielding 82 patients who were allocated to either the HFRT group (n=41) or the standard-of-care (SOC) group (n=41), based on whether they received HFRT to pulmonary metastases. All patients received systemic regimens in accordance with guideline-recommended standard care; those in the HFRT group additionally underwent volumetric modulated arc therapy (VMAT). We compared short-term response, progression-free survival (PFS), overall survival (OS), and safety profiles between the two groups. Survival rates were estimated using the Kaplan-Meier method, and multivariate prognostic analyses were conducted using Cox regression models.

Results

After matching, each group consisted of 41 patients. With a median follow-up of 32.1 months, the HFRT group demonstrated significantly better short-term response (P=0.038), PFS (P=0.037), and OS (P=0.038) compared with the SOC group. Independent prognostic factors for PFS included the addition of HFRT and the type of systemic therapy; for OS, independent factors were HFRT use, systemic regimen, and the number of metastatic lesions. Adverse events were manageable in both treatment arms.

Conclusion

In patients with advanced NSCLC presenting with pulmonary oligoprogression after first-line systemic therapy—particularly those with driver-gene-negative tumors receiving chemo-immunotherapy—the addition of HFRT to metastatic lesions confers favorable outcomes with an acceptable safety profile.

图1 研究人群选择的流程图
表1 PSM前后肺转移瘤患者一般临床资料[例(%)]
表2 2组患者的近期疗效[例(%)]
图2 HFRT组和SOC组的PFS、OS曲线。图a为无进展生存期曲线;图b为总生存期曲线 注:HFRT为大分割放疗组;SOC为标准治疗组;PFS为无进展生存期;OS为总生存期
表3 82例NSCLC肺寡进展患者PFS的单因素+多因素分析
表4 82例NSCLC肺寡进展患者OS的单因素+多因素分析
1
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022 [J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
2
赵瑞芝, 罗京伟, 肖建平, 等. 肺转移瘤大分割精准放疗临床疗效分析 [J]. 中华放射肿瘤学杂志, 2020, 29(8): 639-643.
3
Hellman S, Weichselbaum RR. Oligometastases [J]. J Clin Oncol, 1995, 13(1): 8-10.
4
Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial [J]. JAMA Oncology, 2018, 4(1): e173501.
5
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial [J]. Lancet, 2019, 393(10185): 2051-2058.
6
Gomez D R, Tang C, Zhang J, et al. Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase Ⅱ, randomized study [J]. J Clin Oncol, 2019, 37(18): 1558-1565.
7
Tsai CJ, Yang JT, Shaverdian N, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (consolidative use of radiotherapy to block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study [J]. Lancet, 2024, 403(10422): 171-182.
8
Iyengar P, Hu C, Gomez D, et al. NRG-LU002: randomized phase Ⅱ/Ⅲ trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC) [J]. J Clin Oncol, 2024, 42(16_suppl): 8506-8506.
9
Ricco A, Davis J, Rate W, et al. Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient registry's experience [J]. Radiat Oncol, 2017, 12(1): 35.
10
Kobiela J, Spychalski P, Marvaso G, et al. Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review [J]. Crit Rev Oncol Hematol, 2018, 129: 91-101.
11
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase Ⅱ randomized trial [J]. J Clin Oncol, 2020, 38(25): 2830-2838.
12
Nuyttens JJ, van der Voort van Zyp NC, Verhoef C, et al. Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study [J]. Int J Radiat Oncol Biol Phys, 2015, 91(2): 337-343.
13
Petty WJ, Urbanic JJ, Ahmed T, et al. Long-term outcomes of a phase 2 trial of chemotherapy with consolidative radiation therapy for oligometastatic non-small cell lung cancer [J]. Int J Radiat Oncol Biol Phys, 2018, 102(3): 527-535.
14
Mielgo-Rubio X, Garde-Noguera J, Juan O, et al. Stereotactic body radiation therapy: a good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study [J]. World J Clin Oncol, 2020, 11(12): 983-989.
15
Chen HJ, Tu HY, Hu Y, et al. A phase Ⅱ trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001) [J]. J Hematol Oncol, 2025, 18(1): 3.
16
Chen M, Ma H, Du X, et al. 698 a phase 2 study of durvalumab combined with chemotherapy and stereotactic body radiotherapy (SBRT) in patients with oligometastatic non-small cell lung cancer (NSCLC) (SABRCURE trial)[C]//Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd, 2022: A729-A729.
17
宋丽萍, 赵璨. 晚期EGFR突变NSCLC患者单药与联合化疗或抗血管生成药物治疗效果的真实世界比较分析[J/OL]. 中华临床医师杂志(电子版), 2025, 19(1): 1.
18
Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung [J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl): S70-76.
19
Farr KP, Khalil AA, Grau C. Patient-reported lung symptoms and quality of life before and after radiation therapy for non-small cell lung cancer: correlation with radiation pneumonitis and functional imaging [J]. Acta Oncol, 2019, 58(10): 1523-1527.
20
张永彤, 王春春, 黄芳, 等. 肺癌放射治疗造成急性放射性肺炎的临床治疗研究 [J]. 中国全科医学, 2021, 24(s01): 103-105.
21
营养评估在预测老年食管癌患者放疗及同步放化疗急性不良事件中的作用[EB/OL]. 2026-02-28.
22
Zhou Z, Song X, Wu A, et al. Pulmonary emphysema is a risk factor for radiation pneumonitis in NSCLC patients with squamous cell carcinoma after thoracic radiation therapy [J]. Sci Rep, 2017, 7(1): 2748.
[1] 王雪珂, 邵晓雁, 王若珩, 盛方军, 张有为, 缪肖波. LncRNA EBLN3P/miR-144-3p轴通过调控cAMP/PKA/CREB通路影响非小细胞肺癌放疗敏感性和线粒体损伤的机制研究[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(05): 745-751.
[2] 周叶娟, 王永兵, 李艳. Ⅲ期不可切除非小细胞肺癌治疗新进展[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(05): 905-909.
[3] 李秋韵, 王爽. 基于CT影像学评估非小细胞肺癌免疫治疗疗效的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 705-709.
[4] 刘慧, 赵燕霞, 汪海涛, 魏肖慧, 魏雪梅. CT肿瘤内部异质性对NSCLC患者免疫治疗反应性的预测价值[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 560-565.
[5] 李春艳, 郎广碧, 周亚, 陈晓龙, 胡明冬. 胸部SMARCA4缺失型非小细胞肺癌与SMARCA4缺失型未分化肿瘤的组织病理学特征、影像学表现及预后分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 534-541.
[6] 黄丛秀, 王少军, 郁志龙, 苏乌云, 刘彩霞, 孙晓革. 局部晚期非小细胞肺癌放疗联合免疫治疗并发治疗相关性肺炎的危险因素分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 566-571.
[7] 李洋, 陈雨欣, 高娜, 李继霞, 米晶晶, 贺元, 曹鸿鑫. 不同剂量贝伐珠单抗联合培美曲塞及铂类药物治疗晚期NSCLC疗效与安全性倾向性匹配分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 578-585.
[8] 丁海斌, 刘爽, 乔丹, 李新涛, 陈艳妮, 程蒿, 刘佳. 外周血炎症指数预测148例局部晚期NSCLC免疫化疗后MPR的临床意义[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 600-606.
[9] 陈玥, 吴丙琳, 冯妮娜, 杨勤秦, 苗雄伟, 尚苗苗, 马静, 王欢, 任巧微. 中性粒细胞/淋巴细胞比值预测免疫治疗联合化疗晚期NSCLC患者预后的临床意义[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 607-614.
[10] 陈希, 范海华, 倪婷婷, 宋丽, 邵丽丽. cfDNA、NLR及PD-L1联合检测对42例非小细胞肺癌患者免疫治疗疗效的预测意义[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(03): 405-410.
[11] 毛燕青, 张妤, 付婷, 王翎, 王娟, 梁容瑞. Revolution CT能谱成像技术联合p53、GAGE7表达在非小细胞肺癌诊断中临床意义[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(03): 431-436.
[12] 许猛军, 殷海涛, 史凌云, 马高磊, 张英楠, 郭雯雯, 王曼, 张静雅, 刘枫, 陈远远. 不同剂量调强放疗对144例局部晚期非小细胞肺癌患者的疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(03): 476-479.
[13] 刘佳铭, 文健, 孙晓容, 钟瑶, 张雯. 慢性阻塞性肺疾病合并肺癌免疫检查点抑制剂相关重症皮疹一例[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(02): 353-355.
[14] 黄佳, 潘汉博, 田禹, 沈凡, 林凯临, 李剑涛, 林皓, 陈天翔, 成兴华, 罗清泉. 机器人辅助胸腔镜手术治疗非小细胞肺癌的围手术期和长期生存结局:基于上海市胸科医院13年临床实践的真实世界研究[J/OL]. 中华胸部外科电子杂志, 2026, 13(03): 181-188.
[15] 武强, 苏文泉, 汪淑晶, 雷霆. 围手术期派安普利单抗联合安罗替尼±化疗治疗可切除非小细胞肺癌的探索:解读ALTER-L043 Ⅱ期临床试验[J/OL]. 中华胸部外科电子杂志, 2026, 13(03): 218-224.
阅读次数
全文


摘要


AI
小
编
AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?